Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1981 Aug;33(2):503-6.
doi: 10.1128/iai.33.2.503-506.1981.

Fibrinogen enhances complement-mediated augmentation of retention of polymorphonuclear leukocytes by nylon columns

Fibrinogen enhances complement-mediated augmentation of retention of polymorphonuclear leukocytes by nylon columns

J P Phair et al. Infect Immun. 1981 Aug.

Abstract

Retention of polymorphonuclear leukocytes (PMN) by nylon columns is significantly increased when PMN are suspended in zymosan-activated plasma. In zymosan-activated plasma, 25.8 +/- 4.9% of PMN were retrained as compared with 11.1 +/- 2.7% suspended in zymosan-activated serum (ZAS) (P = 0.001) and 7.9 +/- 3.2% in fresh serum (P = 0.0005). Addition of heated plasma (56 degrees C for 30 min) to ZAS restored optimal retention. These results suggested a role for a heat-stable factor(s) in plasma, which augmented complement-mediated enhancement of PMN adhesiveness. This study was designed to determine whether fibrinogen enhanced retention by nylon columns of PMN in the presence of activated complement. Addition of defibrinated plasma to ZAS failed to enhance adhesiveness to nylon. The retention of PMN suspended in ZAS was 11.1 +/- 2.7%, as compared with 10.5 +/- 3.7% in ZAS plus defibrinated plasma. Retention of PMN suspended in ZAS plus fibrinogen was 27.92 +/- 13.2% as opposed to 16.35 +/- 7.5% (P = 0.045) in ZAs. In contrast, retention of cells in serum was 12.96 +/- 7.5%. These results suggest that the process which enhances PMN adhesiveness involves the interaction of cells, activated complement, and fibrinogen.

PubMed Disclaimer

References

    1. Br J Haematol. 1967 Jul;13(4):581-90 - PubMed
    1. N Engl J Med. 1974 Sep 26;291(13):642-6 - PubMed
    1. J Allergy Clin Immunol. 1975 Dec;56(6):491-506 - PubMed
    1. J Clin Invest. 1976 Apr;57(4):1098-103 - PubMed
    1. Ann Intern Med. 1977 Jan;86(1):35-9 - PubMed

Publication types

LinkOut - more resources